Clinical Trial Search

Primary: Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours) — 6.92; 6.51 log-transformed total cough count

Primary: Number of Cough Bouts Over 4-hour Postdose Period — 139.6; 131.3; 126.4 Cough bouts — p=0.216

Primary: Change From Baseline in 24-hour Cough Frequency at 14 Weeks — 17.0; 17.0; 12.6; 10.6 Coughs/hour — p=0.99

Primary: Change in Night Cough Score on First Night of Treatment (From N0 to N1) — -5.16; -1.77 change in combined night cough score — p=<0.01

Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml

Primary: Adjusted Mean Change From Baseline in Number of Valid Responses to Rapid Visual Information Processing (RVIP) Cognitive Test — 4.8; 1.3 Valid responses — p=0.0008

Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049

Primary: Adjusted Mean Change From Baseline in Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Total Score — -9.56; -9.11; -26.49; -22.97 score on a scale

Primary: Reduction in Viral Load in the URT — 3.6; 3.3; 4.9; 4.1 log 10 copies/mL — p=0.7146

Primary: Nasal Secretion Weights — 3.5; 4.2; 1.2; 2.6 grams

Primary: Average Nasal Symptom Score Over Days 1-4 (ANSS1-4) — 3.428; 3.336 Score on a scale — p=0.516

Primary: Leicester Cough Questionnaire (LCQ) — 3.2; 2.06 score on a scale — p=.23

Primary: Number of Participants With Rhinovirus-associated Illness Episodes — 63; 60 Participants

Primary: Change in Leicester Cough Questionnaire Score — 6.61; 2.07 score on a scale

Primary: Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A) — 152.7; 192.5 cough count

Primary: Breathing Scores Post 15 Minutes — 0.83; 0.11 Score on a Scale — p=<0.0001

Primary: Number of Subjects With Serious Adverse Events — 0; 0 Participants

Primary: Total Symptom Score (TSS) Over Days 2 to 4 (TSS2-4) — 6.390; 5.777 units on a scale — p=0.0895

Primary: Investigator's End of Study Assessment of Treatment — 163; 149 participants — p=0.0096

Primary: Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population — 67; 64; 21; 27 Participants

Primary: Change in Cough Reflex Sensitivity to Capsaicin — 0.97; 0.80; 0.57 log C5 (uM)

Primary: Cough Frequency Measurement — 6.6; 2.7; 2.5; 12.7 coughs per hour over a 24 hour monitorin

Primary: Symptom Severity Assessment at 15 Minutes — 10.66; 10.64; -1.11; -1.13 Score on scale — p=0.9473

Primary: Part A: Cough Frequency Per Hour, Assessed Objectively Over 24 Hours Using VitaloJAK® Cough Recorder — 14.88; 17.30; 12.61; 13.21 coughs/hour

Primary: Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. — 7.6; 9.5 Number of days — p=0.023

Primary: Relief of Upper Respiratory Tract Infection (URI) Symptoms (Cough, Runny Nose, Nasal Congestion, Sneezing)1 Hour After Dose of Homeopathic Remedy. — 83; 100; 94; 52 doses

Primary: Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period — -1.75; -0.73 Score…

Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale

Primary: Relative Change From Baseline in 24-hour Cough Frequency at Day 21 — -64.92; -9.36 coughs per hour — p=<0.0001

Primary: Physician Global Evaluation of Effectiveness on Nasal Symptoms — 1.9; 2.1 score on a scale